Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if nivolumab combined with ISA101 can
help to control cancer that has spread. The safety of the study drugs will also be studied.
This is an investigational study. ISA101 is not FDA approved or commercially available. It is
currently being used for research purposes only. Nivolumab is FDA approved to treat certain
types of melanoma in patients who no longer respond to other drugs. Combining ISA101 with
nivolumab is investigational. The study doctor can explain how the study drugs are designed
to work.
Up to 28 participants will be enrolled in this study. All will take part at MD Anderson.